Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study
Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating...
Company
Simcere’s SIM0237 Receives NMPA Approval for Bladder Cancer Trial
China-based pharmaceutical innovator Simcere Pharmaceutical Group (HKG: 2096) has announced the receipt of an additional...
Abbisko Therapeutics to Unveil Phase I Data for ABSK011 and ABSK043 at ESMO 2023
Shanghai-based biotech powerhouse Abbisko Therapeutics Co., Ltd (HKG: 2256) is preparing to present the results...
MicroPort CardioFlow Medtech’s Third-Generation TAVI Product Achieves Initial Clinical Success
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...
Suzhou Inhal Pharma Secures Series A Funding for Expansion and Clinical Advances
Suzhou Inhal Pharma Co., Ltd, a China-based company dedicated to the research and development of...
CANbridge’s Maralixibat Receives Priority Review for PFIC Treatment in China
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced that a New Drug...
WuXi Biologics Launches WuXiUI: A Revolutionary Biotech Patent Platform
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...
Fosun Pharma Initiates Phase III Trial for ET-26 Anesthetic in China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...
Kelun-Biotech to Present SKB264 Study Results for Metastatic Breast Cancer at ESMO
China-based pharmaceutical innovator Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its subsidiary Sichuan Kelun-Biotech...
Vcanbio Receives NMPA Approval for Stem Cell Therapy VUM02 Clinical Trial
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...
Nona Biosciences Partners with Ingenia for Immunological Therapeutics Development
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142) and a biotech company...
SciClone Pharmaceuticals Gains FDA Nod for Thymalfasin COVID-19 Vaccine Booster Study
SciClone Pharmaceuticals Inc. (HKG: 6600), formerly a US-based and Nasdaq-listed company, has announced that it...
Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671
China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly...
Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round
Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai...
Hainan Poly Pharm’s PL002 Accepted for FDA Review for Liver Cancer Surgery
China-based pharmaceutical company Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that the Investigational...
Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a...
Pfizer’s Velsipity Approved by FDA for Ulcerative Colitis Treatment
China-based pharmaceutical company Everest Medicines (HKG: 1952) announced that its licensing partner, Pfizer Inc. (NYSE:...
Pfizer Adjusts 2023 Revenue Projections Amidst Decreased COVID-19 Solution Demand
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has revised its projected 2023 revenues downward, reflecting a...
FDA Approves Pfizer’s Braftovi + Mektovi Combo for BRAF V600E Metastatic NSCLC
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) regulatory approval for...